肿瘤的免疫治疗现状及发展方向
The Current Strategies and Developing Directions of Tumor Immunotherapy
DOI: 10.12677/WJCR.2019.93014, PDF,   
作者: 胡雨薇, 谭 源, 姚妍竹, 何雨婷, 熊 雨, 梁琼文, 时樱溪：电子科技大学医学院，四川 成都；胡火珍*：四川大学生命科学学院，四川 成都
关键词: 肿瘤；免疫疗法；过继性细胞免疫治疗；肿瘤疫苗；免疫检查点；Tumor； Immunotherapy； Adoptive Cellular Immunotherapy； Tumor Vaccine； Immune Checkpoint
摘要: 随着肿瘤学、免疫学及分子生物学等学科的不断发展，肿瘤免疫治疗及转化研究也取得了巨大的成就，为抗肿瘤治疗模式带来了革命性的改变。免疫治疗发展潜力巨大，今后也将成为精准医疗的关键武器，但目前也面临着诸多挑战。本文将从特异性的及非特异性的肿瘤过继免疫治疗、免疫检验点阻断(ICIs)等几个方面来论述免疫治疗的现状及发展方向。
Abstract: With the continuous development of oncology, immunology and molecular biology, tumor immuno-therapy and transformation research have made great achievements, bringing revolutionary changes to the anti-tumor treatment models. The development potential of immunotherapy is huge, and it will become a key weapon for precision medicine in the future, but it also faces many challenges. This review will discuss the current strategies and development directions of immunotherapy from specific and non-specific tumor adoptive immunotherapy, immunological checkpoint blockade (ICIs) etc.
文章引用：胡雨薇, 谭源, 姚妍竹, 何雨婷, 熊雨, 梁琼文, 时樱溪, 胡火珍. 肿瘤的免疫治疗现状及发展方向[J]. 世界肿瘤研究, 2019, 9(3): 98-103. https://doi.org/10.12677/WJCR.2019.93014

参考文献

[1] 张叔人. 肿瘤免疫治疗进展[M]. 北京: 中国协和医科大学出版社. 2017: 175.
[2] 上海细胞治疗工程技术中心. 人类癌症与免疫治疗发展史[EB/OL]. https://mp.weixin.qq.com/s?__biz=MzA4MDI2NTMzMA==&mid=2651685914&idx=1&sn =dcd2fa930040d1d113a19c9492b82aac&chksm= 845fcd07b328441154e8fe67d5ff1ded28a6de9912b 85de08bfd224dce103ee0fde0c078420f&mpshare= 1&scene=23&srcid=0502KmyH8J6gSCt1Z8egeInV#rd, 2019-05-10.
[3] 王胜军. 鼻咽癌的细胞毒性T细胞免疫治疗的定量研究[M]. 博士学位论文, 2019.
[4] 姜华. EB病毒特异性细胞毒性T淋巴细胞与肿瘤免疫治疗研究进展[J]. 国外医学免疫学分册, 2001, 24(5): 240.
[5] Straathof, K.C., Bollard, C.M., Popat, U., et al. (2005) Treatment of Nasopharyngeal Carcinoma with Epstein-Barr Virus-Specific T Lymphocytes. Blood, 105, 1898-1904.
[Google Scholar] [CrossRef] [PubMed]
[6] Comoli, P., Pedrazzoli, P., Maccario, R., et al. (2005) Cell Therapy of Stage IV Nasopharyngeal Carcinoma with Autologous Epstein-Barr Virus-Targeted Cytotoxic T Lympho-cytes. Journal of Clinical Oncology, 23, 8942-8949.
[Google Scholar] [CrossRef] 
[7] 蔡亮, 张凌华, 杨子杰, 裘丽珍. 嵌合抗原受体T细胞(CAR. T)免疫疗法: 绝处逢生的利剑[J]. 自然杂志, 2016, 38(3): 228-231.
[8] 张兰林, 吴向华. TCR-T细胞免疫疗法在实体肿瘤治疗中的研究进展[J]. 肿瘤, 2018, 38(3): 256-263.
[9] Morgan, R.A., Dudley, M.E., Wunderlich, J.R., et al. (2006) Cancer Regression in Patients after Transfer of Genetically Engineered Lymphocytes. Science, 314, 126-129.
[Google Scholar] [CrossRef] [PubMed]
[10] 陈怡. 自体免疫免疫细胞治疗技术之CIK细胞治疗癌症[J]. 生物技术世界, 2016(4): 329.
[11] 王志华. CIK细胞治疗癌症-国际临床试验的现状及展望[J]. 中国肿瘤生物治疗杂志, 2013(2).
[12] 百度. 肿瘤免疫治疗[EB/OL].
https://baike.baidu.com/item/肿瘤免疫治疗/8945917?fr=Aladdin, 2019-05-06.
[13] 曹雪涛, 叶天垦, 杨嗣坤. IL-2激活的TIL与LAK细胞体内抗肿瘤作用的比较[J]. 中国免疫学杂志, 1990, 21(6): 105-110.
[14] Horn, S.S. (1991) Common Expression Melanoma Tu-mor-Specific Antigen Recognized by Human Tumor-Infiltrating Lymphocytes: Analysis by Human Lympho-cyte-Antigenrestriction. Immunotherapy, 2, 153-164.
[Google Scholar] [CrossRef] 
[15] 隋爱霞, 赵静, 郭晓强. 免疫检验点阻断: 癌症免疫治疗的新希望[J]. 科学, 2016, 68(2): 20-23.
[16] Rosenberg, S.A., 俞慕华. 白细胞介素2免疫治疗癌症的现状与展望[J]. 国际生物制品学杂志, 1989(1): 8-11.
[17] Kyrgios, M. and Shafi, M.I. (2009) HPV Vaccine. Obstetrics Gynecology and Reproductive Medicine, 19, 26-28.
[Google Scholar] [CrossRef] 
[18] 小邢爱知识. 深度剖析: 肿瘤疫苗的应用与前景[EB/OL]. http://oncol.dxy.cn/article/104350, 2019-05-10.
[19] A+医学. 免疫与健康/肿瘤疫苗[EB/OL]. http://www.a-hospital.com/w/%E5%85%8D%E7%96%AB%E4%B8%8E%E5%81%A5%E5%BA%B7/%E8%82%BF%E7%98%A4%E7%96%AB%E8%8B%97, 2019-05-07.
[20] Mogul, A., Terme, M. and Tanchot, C. (2019) Thera-peutic Cancer Vaccine and Combinations with Antiangiogenic Therapies and Immune Checkpoint Blockade. Frontiers in Immunology, 10, Article 467.
[21] 万岩岩. 肿瘤多肽疫苗研究进展[J]. 动物医学进展, 2015, 36(2): 101-105.
[22] Patrick, A.O., Hu, Z.T., Keskinen, D.B., et al. (2017) An Immunogenic Personal Neoantigen Vaccine for Patients with Melanoma. Nature, 547, 217-221.
[23] 吴亚洪, 高艳锋, 祁元明. 肿瘤抗原细胞毒性T淋巴细胞表位鉴定和多肽疫苗的研究进展[J]. 郑州大学报医学版, 2011, 45(5): 657-660.
[24] Shahin, U., Derhovanessian, E., Miller, M., et al. (2017) Personalized RNA Mechanome Vaccines Mobilize Poly-Specific Therapeutic Immunity against Cancer. Nature, 547, 222-226.

为你推荐